Professional support for development, working hand in hand to create the future
2022year1month21Today, Zhenchuanghui “Professional Support for Development, Working Together to Create the Future”2022New Year's Special Salon on Biopharmaceutical Enterprise Financing and Intellectual Property Rights, held at Furonghua Road in the Shanghai International Medical College Area500make2Building No.5The Layer Conference Hall was successfully held. This event was hosted by Zhenyue Capital and co-hosted by Haining Juanhu Science and Technology City and Wanku Medical Technology Incubator. Frost & SullivanFrost & SullivanGuo Jing, the consulting director of Frost & Sullivan's Greater China region, was invited to attend and participate in an interactive salon session.IDGCapital Medical Group Investment Manager Ouyang Yifan, Partner Dr. Qi Fang from Fanda Law Firm Dr. Zhao Bing, Director of the Research Institute at Huaxing Securities and Chief Analyst for the Pharmaceutical Industry, joined forces with us to discuss a series of topics including current medical industry policies.
Interactive Salon Session
The interactive salon session is atIDGThe atmosphere was lively under the chairmanship of Ouyang Yifan, Investment Manager of Capital Medical Group. Dr. Qi Fang, a partner at Fangda Law Firm Dr. Zhao Bing, Director of the Research Institute at Huaxing Securities and Chief Analyst for the Pharmaceutical Industry, and Guo Jing, Consulting Director for Greater China at Frost & Sullivan, participated in this session. The four guests engaged in discussions and exchanges around a series of topics, including the impact of current medical industry policies and capital environment on the financing and valuation of healthcare enterprises, whether domestic market innovative drug and medical device companies should adopt localization or internationalization strategies, how local enterprises can quickly break through European and American patent layouts to promote product launches, knowledge production areas that need attention for overseas development, and the impact of population aging on the future development of China's pharmaceutical industry. Representatives from enterprises and institutions attending the event also actively participated in interactive exchanges, expressing their views on how they view the future development of China's pharmaceutical industry.
Topic Sharing Session
Topic 1: The Impact of Crafting Good Investment Stories on the Valuation of Pharmaceutical Companies
Dr. Zhao Bing introduced the root causes of current differences in foreign investors' understanding of investment stories, and shared how to restructure investment stories from four aspects: financial systems, listing rules, investor backgrounds, and differences in the pharmaceutical industry between different countries, making the investment stories more suitable for overseas investors.
Wonderful Insights:
1The root cause of differences in valuation systems lies in financial systems, issuance systems, the economic development levels of various countries, and the stage of development of the healthcare industry.
2Sort out investment stories with the perspective of industry panorama.
3Starting from the investor's background, we respect the differences in their thinking and habits, and tell stories that investors can understand.
Topic 2: Examination and Analysis of Intellectual Property Rights in Pharmaceutical Enterprises
Dr. Qi Fang emphasized the importance of intellectual property rights from the perspective of the development of China's legal framework for patent linkage systems, drug patent protection strategies, and common intellectual property issues faced by pharmaceutical companies. From a professional standpoint, he analyzed potential problems in the field of intellectual property rights for pharmaceutical companies, earning high recognition from entrepreneurs and institutions present.
Wonderful Insights:
1The patent link system allows generic drug companies to start manufacturing before the expiration of the original research drug's patent without worrying about their research and filing activities being deemed as patent infringement. It encourages generic drug companies to initiate patent challenges, promoting early resolution of pharmaceutical patent infringement disputes.
2The main types of pharmaceutical patents include active ingredients, preparation methods, specific uses, prodrugs or metabolites, etc.
3, freely implementedFTOThrough retrieval, it is confirmed whether the product can be freely implemented after its market launch, that is, whether it may infringe upon others' intellectual property rights due to aspects such as manufacturing, use, promised sales, sale, import of products, etc.
4Authorize the introduction (License in progress) Two aspects that require attention: down payment+milestone payment+Future sales commissions; licensing arrangements under different circumstances such as non-compete agreements, whether involving cross-border production and supply, and exclusive rights.
